UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Bone remodeling

Läkartidningen, 2006, Vol.103 (40), p.2972-2975

2006

Volltextzugriff (PDF)

Hearing is not affected by diphosphonates in osteogenesis imperfecta. Retrospective study of 42 medical records

Läkartidningen, 2011-09, Vol.108 (39), p.1906-1909

2011

Volltextzugriff (PDF)

Diphosphonates can cause necrosis of the jaw. Patients with malignant skeletal diseases are at risk

Läkartidningen, 2006-05, Vol.103 (21-22), p.1741

2006

Volltextzugriff (PDF)

Alternative account of therapeutic effects in osteoporosis

Läkartidningen, 2001-10, Vol.98 (42), p.4624-4624

2001

Volltextzugriff (PDF)

Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women

Osteoporosis international, 2008-06, Vol.19 (6), p.811-818

2008

Volltextzugriff (PDF)

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

The Lancet (British edition), 2016-03, Vol.387 (10024), p.1163-1177

2016

Volltextzugriff (PDF)

Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study

Journal of rheumatology, 2008-03, Vol.35 (3), p.488

2008

Volltextzugriff (PDF)

Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-Month Analysis of the E-ZO-FAST Trial

Clinical breast cancer, 2012-02, Vol.12 (1), p.40-48

2012

Volltextzugriff (PDF)

Bisphosphonates, Old Friends of Bones and New Trends in Clinics

Journal of medicinal chemistry, 2021-02, Vol.64 (3), p.1260-1282

2021

Volltextzugriff (PDF)

Targeted delivery to bone and mineral deposits using bisphosphonate ligands

Advanced drug delivery reviews, 2016-04, Vol.99 (Pt A), p.12-27

2016

Volltextzugriff (PDF)

Osteoarthritis phenotypes and novel therapeutic targets

Biochemical pharmacology, 2019-07, Vol.165, p.41-48

2019

Volltextzugriff (PDF)

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

The lancet oncology, 2016-02, Vol.17 (2), p.243-256

2016

Volltextzugriff (PDF)

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

Annals of oncology, 2015-02, Vol.26 (2), p.313-320

2015

Volltextzugriff (PDF)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

The journal of clinical endocrinology and metabolism, 2016-08, Vol.101 (8), p.3163-3170

2016

Volltextzugriff (PDF)

Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2017-01, Vol.317 (1), p.48

2017

Volltextzugriff (PDF)

Trends in Media Reports, Oral Bisphosphonate Prescriptions, and Hip Fractures 1996–2012: An Ecological Analysis

Journal of bone and mineral research, 2015-12, Vol.30 (12), p.2179-2187

2015

Volltextzugriff (PDF)

Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial

JAMA internal medicine, 2015-06, Vol.175 (6), p.913

2015

Volltextzugriff (PDF)

International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease

Journal of clinical oncology, 2013-06, Vol.31 (18), p.2347-2357

2013

Volltextzugriff (PDF)

Impact of Farnesylation Inhibitors on Survival in Hutchinson-Gilford Progeria Syndrome

Circulation (New York, N.Y.), 2014-07, Vol.130 (1), p.27-34

2014

Volltextzugriff (PDF)

Bisphosphonate therapy for osteogenesis imperfecta

Cochrane database of systematic reviews, 2014-07 (7), p.CD005088-CD005088

2014

Volltextzugriff (PDF)

Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307

JNCI : Journal of the National Cancer Institute, 2020-07, Vol.112 (7), p.698-707

2020

Volltextzugriff (PDF)

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

The Lancet (British edition), 2010-12, Vol.376 (9757), p.1989-1999

2010

Volltextzugriff (PDF)

Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study

Osteoporosis international, 2016-01, Vol.27 (1), p.21-31

2016

Volltextzugriff (PDF)

A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?

Osteoporosis international, 2017-08, Vol.28 (8), p.2465-2473

2017

Volltextzugriff (PDF)

1 – 25 von 4.146

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(3.564)
Mit Volltextzugriff
(3.051)

Publikationsform

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(3.510)
Diphosphonates - Administration & Dosage
(3.287)
Science & Technology
(3.051)
Life Sciences & Biomedicine
(2.979)
Female
(2.498)
Male
(1.728)
Bone Density Conservation Agents - Administration & Dosage
(1.641)
Diphosphonates - Therapeutic Use
(1.541)
Middle Aged
(1.472)
Aged
(1.455)
Diphosphonates - Adverse Effects
(1.121)
Bisphosphonates
(987)
Biological And Medical Sciences
(973)
Imidazoles - Administration & Dosage
(931)
Osteoporosis
(915)
Medical Sciences
(909)
Bone Density Conservation Agents - Therapeutic Use
(763)
Osteoporosis - Drug Therapy
(726)
Bone Density Conservation Agents - Adverse Effects
(713)
Animals
(696)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Osteoporosis International
(167)
Journal Of Bone And Mineral Research
(124)
Bone
(120)
Clinical Calcium
(73)
Calcified Tissue International
(69)
Journal Of Oral And Maxillofacial Surgery
(57)
Nihon Rinshō
(41)
Journal Of Clinical Oncology
(39)
Supportive Care In Cancer
(39)
The Lancet
(37)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Bone remodeling

Hearing is not affected by diphosphonates in osteogenesis imperfecta. Retrospective study of 42 medical records

Diphosphonates can cause necrosis of the jaw. Patients with malignant skeletal diseases are at risk

Alternative account of therapeutic effects in osteoporosis

Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study

Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-Month Analysis of the E-ZO-FAST Trial

Bisphosphonates, Old Friends of Bones and New Trends in Clinics

Targeted delivery to bone and mineral deposits using bisphosphonate ligands

Osteoarthritis phenotypes and novel therapeutic targets

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial

Trends in Media Reports, Oral Bisphosphonate Prescriptions, and Hip Fractures 1996–2012: An Ecological Analysis

Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial

International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease

Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial

Impact of Farnesylation Inhibitors on Survival in Hutchinson-Gilford Progeria Syndrome

Bisphosphonate therapy for osteogenesis imperfecta

Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study

A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?

Suchergebnisse filtern